Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUILT-2.021: ALT-803 Maintenance in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT03054909Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2017
- Primary completion
- Feb 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Masonic Cancer Center. Started Sep 2017; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03054909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054909.